Blawg Search - Law Blogs, Lawyer Blogs, Legal Blogs Directory & Search Engine

"Allergan suing FDA over off-label policy": The Associated Press has a report that begins, "Allergan Inc., the maker of the Botox wrinkle treatment, challenged the government's ban on off-label drug marketing to doctors, saying it violates the company's right to freedom of speech." According to The AP's report, "Allergan is represented in its lawsuit by Paul D. Clement, a partner at King & Spalding LLP in Washington, D.C., and formerly the Solicitor General ...

The United States District Court for the District of Delaware handed Allergan, Inc. (NYSE:AGN) a victory last week in its patent infringement lawsuit brought against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd., Apotex, Inc. and Apotex Corp. The defendants had been seeking permission to market generic versions of Allergan's drugs ALPHAGAN® P, which is indicated [...] No related posts. Related posts brought to you by Yet Another Related Posts Plugin.

The FDA has just issued a subpoena to Botox maker, Allergan Inc., to obtain marketing related documents from the company about the use of the defective drug for headaches. Botox is generally used to relax wrinkles. Here, however, FDA suspects that the Botox maker is attempting to promote the defective product to relieve pain from headaches, which, no pun intended, FDA is frowning upon. FDA is presently looking at Botox and similar ...

Allergan Inc., the makers of Botox, and it's sister product, Botox Cosmetic, are bringing a lawsuit against the United States, the FDA and it's commissioner, Margaret Hamburg, as well as the Kathleen Sebelius, secretary ... this lawsuit is an attempt to cripple the FDA which serves an important and valid purpose for the general public. A victory for Allergan clearly creates a slippery slope for drug manufacturers who will be able to enter a product into the market for one purpose and then promote ...

... patents within a corporate enterprise - Novartis Pharm. Corp. v. Teva Pharm. USA, Inc. (Property, intangible) US: How do you solve a problem like Sidewiki (FDA Law ... maleate): US: Patent infringement suit following a Paragraph IV certification Allergan, Inc. v. Alcon Laboratories, Inc. et al. (Patent Docs) Dovonex (Calcipotriol) - UK: ... in response to Paragraph IV certification - Novartis AG et al. v. Apotex Inc. et al. (Patent Docs) Prandimet (Repaglinide and Metformin) - US: Patent infringement ...

/**/ The makers of Botox, Allergan Inc., recently filed a lawsuit against the FDA. The lawsuit is in light of the FDA's regulations that ban drug companies, like Allergan, from marketing drugs for uses that haven't been approved ... illnesses like cerebral palsy. However, they are not permitted to market the application for cerebral palsy or other unapproved uses. Allergan claims in their lawsuit that the ban violates the first amendment and prevents them from providing valid and true information ...

... , 2007), the District Court for the District of Maryland denied Baltimore-based Lupin Pharmaceuticals, Inc.'s (LPI) motion to dismiss an action against it and its parent, Mumbai, India-based ... a cause of action for induced infringement under § 271(e)(2), Allergan, Inc. v. Alcon Labs., Inc., 324 F.3d 1322, 1331 (Fed. Cir. ... curiam), and also acknowledged that other district courts before and after Allergan have disagreed about whether inducement liability exists for entities that were not the named ...

... products industry. ... Prior to joining I Flow Corp., from 1986 to 1990, Mr. Earhart was a corporate officer and the President of the Optical Division of Allergan, Inc. Prior to his employment at Allergan; he was a corporate officer and Division President of Bausch and Lomb and was an operations manager of Abbott Laboratories. He has also served as an engineering consultant at Peat, Marwick, Mitchell & Co. and ...

... patents within a corporate enterprise - Novartis Pharm. Corp. v. Teva Pharm. USA, Inc. (Property, intangible) US: How do you solve a problem like Sidewiki (FDA Law ... maleate): US: Patent infringement suit following a Paragraph IV certification Allergan, Inc. v. Alcon Laboratories, Inc. et al. (Patent Docs) Dovonex (Calcipotriol) - UK: ... in response to Paragraph IV certification - Novartis AG et al. v. Apotex Inc. et al. (Patent Docs) Prandimet (Repaglinide and Metformin) - US: Patent infringement ...

... to market generic tablets containing escitalopram oxalate ("EO"), the active ingredient in Lexapro®. Forest Laboratories, Inc., which owns the patent for Lexapro®, sued Ivax under the Hatch-Waxman Act, which provides that the ... the district court to include Cipla within the scope of the injunction." The Federal Circuit cited Allergan, Inc. v. Alcon Labs, Inc., 324 F.3d 1322 (Fed. Cir. 2003) for the notion that merely filing an ANDA is a constructive act of infringement, and may support a cause of ...